Calamos Advisors
MDGL icon

Calamos Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Calamos Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$882K Sell
1,642
-1,848
-53% -$947K ﹤0.01% 768
2026
Q1 		$1.83M Sell
3,490
-3,076
-47% -$1.47M 0.01% 686
2025
Q4 		$3.82M Buy
6,566
+2,081
+46% +$1.06M 0.01% 561
2025
Q3 		$2.06M Buy
+4,485
New +$1.67M 0.01% 622
2024
Q3 		– Sell
-4,112
Closed -$1.15M – 977
2024
Q2 		$1.15M Buy
4,112
+499
+14% +$119K 0.01% 633
2024
Q1 		$965K Buy
+3,613
New +$851K ﹤0.01% 647

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Calamos Advisors's MDGL Position: Q2 2026 in Review

Calamos Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 53% in Q2 2026, selling an estimated $947K and leaving 1,642 shares worth $882K. The position accounts for ﹤0.01% of the portfolio, ranked #768.

Calamos Advisors first reported a position in MDGL in Q1 2024 and has held it in 6 quarters since. The position peaked at $3.82M in Q4 2025. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Calamos Advisors held 1,642 shares of Madrigal Pharmaceuticals worth $882K as of Q2 2026.
  • Calamos Advisors sold 1,848 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $947K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #768 holding.
  • Calamos Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Calamos Advisors's Madrigal Pharmaceuticals position peaked at $3.82M in Q4 2025.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.